Realm's atopic dermatitis candidate misses in Phase II

Realm Therapeutics plc (LSE:RLM; NASDAQ:RLM) reported preliminary data from a Phase II trial in 122 patients with mild to moderate atopic dermatitis

Read the full 223 word article

User Sign In